Survival Outcome and Prognostic Factors of Primary Spinal Cord Lymphoma.

IF 0.8 4区 医学 Q4 CLINICAL NEUROLOGY
Ding Qianjin, Cheng Zhenguo, Wang Yang, Du Baoshun, Sun Laiguang
{"title":"Survival Outcome and Prognostic Factors of Primary Spinal Cord Lymphoma.","authors":"Ding Qianjin, Cheng Zhenguo, Wang Yang, Du Baoshun, Sun Laiguang","doi":"10.5137/1019-5149.JTN.41081-22.3","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>To identify the predictive factors associated with the survival of patients with a diagnosis of primary spinal cord lymphoma (PSCL).</p><p><strong>Material and methods: </strong>The Surveillance, Epidemiology, and End Results (SEER) database was used in this study, which involved 254 patients with PSCL. Data on the patients' age, sex, race, pathology, Ann Arbor stage, adjuvant therapy, and year of diagnosis were collected. Univariate and multivariate Cox regression models were conducted to detect the predictive variables.</p><p><strong>Results: </strong>Of the 254 patients, 67 (26.4%) die from lymphoma at the time of data collection. Cancer-specific survival at 1, 3, and 5 years was 81.0%, 74.6%, and 74.1%, respectively. Diffuse large B-cell lymphoma (DLBL) was the highest prevalent histotype (n=140, 55.1%). The multivariate Cox regression models revealed that chemotherapy (hazard ratio (HR): 0.47; 95% confidence interval (CI), 0.16-0.82; p=0.040) and radiochemotherapy (HR: 0.43; 95% CI, 0.10-0.57; p=0.045) were independent predictors of favorable cancer-specific survival, whereas age - 80 years (HR: 6.51; 95% CI, 1.65-25.64; p=0.003) and DLBL (HR:1.71; 95% CI, 1.02-2.88; p=0.030) were independently associated with poor cancer-specific survival.</p><p><strong>Conclusion: </strong>The survival outcome of PSCL is favorable in the current treatment strategy. Chemotherapy and radiochemotherapy were predictors of favorable outcomes, whereas older age and DLBL were associated with poor prognosis.</p>","PeriodicalId":23395,"journal":{"name":"Turkish neurosurgery","volume":"1 1","pages":"216-223"},"PeriodicalIF":0.8000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Turkish neurosurgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5137/1019-5149.JTN.41081-22.3","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Aim: To identify the predictive factors associated with the survival of patients with a diagnosis of primary spinal cord lymphoma (PSCL).

Material and methods: The Surveillance, Epidemiology, and End Results (SEER) database was used in this study, which involved 254 patients with PSCL. Data on the patients' age, sex, race, pathology, Ann Arbor stage, adjuvant therapy, and year of diagnosis were collected. Univariate and multivariate Cox regression models were conducted to detect the predictive variables.

Results: Of the 254 patients, 67 (26.4%) die from lymphoma at the time of data collection. Cancer-specific survival at 1, 3, and 5 years was 81.0%, 74.6%, and 74.1%, respectively. Diffuse large B-cell lymphoma (DLBL) was the highest prevalent histotype (n=140, 55.1%). The multivariate Cox regression models revealed that chemotherapy (hazard ratio (HR): 0.47; 95% confidence interval (CI), 0.16-0.82; p=0.040) and radiochemotherapy (HR: 0.43; 95% CI, 0.10-0.57; p=0.045) were independent predictors of favorable cancer-specific survival, whereas age - 80 years (HR: 6.51; 95% CI, 1.65-25.64; p=0.003) and DLBL (HR:1.71; 95% CI, 1.02-2.88; p=0.030) were independently associated with poor cancer-specific survival.

Conclusion: The survival outcome of PSCL is favorable in the current treatment strategy. Chemotherapy and radiochemotherapy were predictors of favorable outcomes, whereas older age and DLBL were associated with poor prognosis.

原发性脊髓淋巴瘤的生存结局和预后因素。
目的:确定与原发性脊髓淋巴瘤(PSCL)患者生存相关的预测因素。材料和方法:本研究使用监测、流行病学和最终结果(SEER)数据库,纳入254例PSCL患者。收集患者的年龄、性别、种族、病理、安娜堡分期、辅助治疗和诊断年份等数据。采用单因素和多因素Cox回归模型检测预测变量。结果:254例患者中,有67例(26.4%)在数据收集时死于淋巴瘤。1年、3年和5年的癌症特异性生存率分别为81.0%、74.6%和74.1%。弥漫性大b细胞淋巴瘤(DLBL)是最常见的组织类型(n=140, 55.1%)。多因素Cox回归模型显示,化疗(风险比(HR): 0.47;95%置信区间(CI), 0.16-0.82;p=0.040)和放化疗(HR: 0.43;95% ci, 0.10-0.57;p=0.045)是有利的癌症特异性生存的独立预测因子,而年龄- 80岁(HR: 6.51;95% ci, 1.65-25.64;p=0.003)和DLBL (HR:1.71;95% ci, 1.02-2.88;P =0.030)与较差的癌症特异性生存率独立相关。结论:在目前的治疗策略下,PSCL患者的生存预后良好。化疗和放化疗是预后良好的预测因素,而年龄和DLBL与预后不良相关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Turkish neurosurgery
Turkish neurosurgery 医学-临床神经学
CiteScore
1.50
自引率
12.50%
发文量
126
审稿时长
2 months
期刊介绍: Turkish Neurosurgery is a peer-reviewed, multidisciplinary, open access and totally free journal directed at an audience of neurosurgery physicians and scientists. The official language of the journal is English. The journal publishes original articles in the form of clinical and basic research. Turkish Neurosurgery will only publish studies that have institutional review board (IRB) approval and have strictly observed an acceptable follow-up period. With the exception of reference presentation, Turkish Neurosurgery requires that all manuscripts be prepared in accordance with the Uniform Requirements for Manuscripts Submitted to Biomedical Journals.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信